Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 3 | 2023 | 593 | 0.750 |
Why?
|
| Oxidative Stress | 7 | 2014 | 1221 | 0.430 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2023 | 378 | 0.350 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 86 | 0.320 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 98 | 0.320 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 337 | 0.300 |
Why?
|
| Cholesterol, LDL | 1 | 2010 | 360 | 0.290 |
Why?
|
| Aryldialkylphosphatase | 6 | 2014 | 18 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 2 | 2022 | 376 | 0.270 |
Why?
|
| Hematopoiesis | 2 | 2022 | 184 | 0.220 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2023 | 16 | 0.210 |
Why?
|
| RNA Splicing Factors | 1 | 2022 | 50 | 0.190 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2021 | 22 | 0.190 |
Why?
|
| Lipids | 4 | 2012 | 616 | 0.170 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 382 | 0.160 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2019 | 52 | 0.160 |
Why?
|
| Antioxidants | 2 | 2014 | 559 | 0.160 |
Why?
|
| Atherosclerosis | 2 | 2012 | 392 | 0.150 |
Why?
|
| Cell Differentiation | 2 | 2023 | 1858 | 0.150 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 245 | 0.140 |
Why?
|
| Serbia | 2 | 2011 | 5 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 124 | 0.100 |
Why?
|
| Reference Values | 2 | 2011 | 791 | 0.100 |
Why?
|
| Volleyball | 1 | 2011 | 10 | 0.090 |
Why?
|
| Malnutrition | 1 | 2012 | 78 | 0.090 |
Why?
|
| Physical Education and Training | 1 | 2011 | 76 | 0.090 |
Why?
|
| Smoking | 2 | 2014 | 1501 | 0.080 |
Why?
|
| Lipoproteins | 1 | 2010 | 170 | 0.080 |
Why?
|
| Weight Gain | 1 | 2012 | 504 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 578 | 0.070 |
Why?
|
| Lipoproteins, HDL | 1 | 2008 | 85 | 0.070 |
Why?
|
| Lipoproteins, LDL | 1 | 2008 | 131 | 0.070 |
Why?
|
| Pregnancy | 3 | 2014 | 6256 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2012 | 561 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 549 | 0.070 |
Why?
|
| Humans | 13 | 2023 | 129078 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2019 | 4867 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2008 | 389 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 3047 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 695 | 0.050 |
Why?
|
| Inflammation | 2 | 2012 | 2696 | 0.050 |
Why?
|
| Malondialdehyde | 2 | 2012 | 28 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2021 | 92 | 0.040 |
Why?
|
| Adult | 6 | 2014 | 35423 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 291 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2012 | 3336 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2012 | 987 | 0.040 |
Why?
|
| Linear Models | 2 | 2012 | 818 | 0.040 |
Why?
|
| Dietary Supplements | 2 | 2014 | 533 | 0.040 |
Why?
|
| Female | 8 | 2014 | 68274 | 0.040 |
Why?
|
| Renal Dialysis | 2 | 2012 | 417 | 0.040 |
Why?
|
| Phenotype | 3 | 2011 | 3062 | 0.030 |
Why?
|
| Proteomics | 1 | 2022 | 988 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 1195 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2014 | 23 | 0.030 |
Why?
|
| Middle Aged | 3 | 2012 | 31024 | 0.030 |
Why?
|
| Vitamins | 1 | 2014 | 173 | 0.030 |
Why?
|
| Advanced Oxidation Protein Products | 1 | 2012 | 1 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 2485 | 0.020 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2012 | 90 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3114 | 0.020 |
Why?
|
| Male | 4 | 2012 | 63248 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2344 | 0.020 |
Why?
|
| Young Adult | 3 | 2012 | 12310 | 0.020 |
Why?
|
| Cholesterol | 1 | 2012 | 400 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2011 | 3290 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 329 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 513 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2012 | 176 | 0.020 |
Why?
|
| Triglycerides | 1 | 2012 | 519 | 0.020 |
Why?
|
| Biomarkers | 2 | 2011 | 3878 | 0.020 |
Why?
|
| Athletic Performance | 1 | 2011 | 77 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 861 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1285 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 265 | 0.020 |
Why?
|
| Paraoxon | 1 | 2008 | 2 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 857 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 1014 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 286 | 0.020 |
Why?
|
| Organophosphorus Compounds | 1 | 2008 | 77 | 0.020 |
Why?
|
| Athletes | 1 | 2011 | 407 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1504 | 0.020 |
Why?
|
| Particle Size | 1 | 2008 | 351 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 639 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 2670 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2012 | 2250 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 1966 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 16583 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2011 | 2088 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 6579 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 7070 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 2016 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 9804 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 34708 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 20241 | 0.010 |
Why?
|
| Child | 1 | 2012 | 20860 | 0.010 |
Why?
|